Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first- line treatment of glioblastoma multiforme (GBM)

被引：0
|
作者：
Shih, K. C.
Spigel, D. R.
Burris, H. A., III
Brown, R. H.
Shepard, G. C.
Hainsworth, J. D.
机构：
[1] Tennessee Oncol PLLC, Nashville, TN USA
[2] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[3] Sarasota Mem Hosp, Florida Canc Specialists, Sarasota, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2075
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
    Ranjan, Tulika
    Desjardins, Annick
    Peters, Katherine B.
    Alderson, Lloyd
    Kirkpatrick, John
    Herndon, James, II
    Bailey, Leighann
    Sampson, John
    Friedman, Allan H.
    Friedman, Henry
    Vredenburgh, James J.
    NEURO-ONCOLOGY, 2012, 14 : 79 - 79
  • [2] Phase II trial of radiation therapy/temozolomide followed by temozolomide/sorafenib in the first-line treatment of glioblastoma multiforme (GBM)
    Lamar, R. E.
    Spigel, D. R.
    Burris, H. A.
    Markus, T. M.
    Kuzur, M.
    Ervin, T.
    Fichtel, L.
    Greco, F. A.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM).
    Vredenburgh, J. J.
    Desjardins, A.
    Reardon, D. A.
    Peters, K.
    Kirkpatrick, J.
    Coan, A. D.
    Bailey, L.
    Janney, D.
    Lu, C.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM).
    Friedman, Henry S.
    Desjardins, Annick
    Peters, Katherine B.
    Reardon, David A.
    Kirkpatrick, John
    Herndon, James Emmett
    Coan, April D.
    Bailey, Leighann
    Sampson, John Howard
    Friedman, Allan H.
    Vredenburgh, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] LONG-TERM FOLLOW-UP OF A PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
    Ranjan, Tulika
    Desjardins, Annick
    Peters, Katherine B.
    Alderson, Lloyd
    Kirkpatrick, John
    Herndon, James, II
    Bailey, Leighann
    Sampson, John
    Friedman, Allan H.
    Friedman, Henry
    Vredenburgh, James
    NEURO-ONCOLOGY, 2012, 14 : 81 - 82
  • [6] BEVACIZUMAB IN COMBINATION WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
    Vredenburgh, James
    Desjardins, Annick
    Reardon, David
    Rich, Jeremy
    Kirkpatrick, John
    Gururangan, Sridharan
    Bailey, Leighann
    Friedman, Allan
    Bigner, Darell
    Friedman, Henry
    NEURO-ONCOLOGY, 2008, 10 (05) : 836 - 837
  • [7] PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION
    Ghiaseddin, Ashley
    Dunn-Pirio, Anastasie
    Peters, Katherine
    Vlahovic, Gordana
    Herndon, James, II
    Threatt, Stevie
    Sampson, John
    Friedman, Allan
    Friedman, Henry
    Desjardins, Annick
    NEURO-ONCOLOGY, 2014, 16
  • [8] A Feasibility Trial of Concurrent Radiation, Temozolomide, and Bevacizumab Followed by Temozolomide and Bevacizumab for Resectable and Unresectable Glioblastoma Multiforme of the Brain
    Liebross, R. H.
    Birhiray, R.
    Schultz, S.
    Payner, T.
    Gupta, N.
    Young, R.
    Cohen-Gadol, A.
    Kuzma, B.
    Givens, S.
    Leagre, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S275 - S275
  • [9] A Feasibility Trial of Concurrent Radiation, Temozolomide, and Bevacizumab followed by Temozolomide and Bevacizumab for Resectable and Unresectable Glioblastoma Multiforme of the Brain
    Liebross, R. H.
    Leagre, C.
    Schultz, S.
    Payner, T.
    Sartorius, C.
    Young, R.
    Cohen-Gadol, A.
    Kuzma, B.
    Givens, S.
    Birhiray, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S125 - S125
  • [10] THE ADDITION OF BEVACIZUMAB TO TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
    Vredenburgh, James J.
    Desjardins, Annick
    Reardon, David A.
    Peters, Katherine B.
    Kirkpatrick, John P.
    Herndon, James E., II
    Coan, April D.
    Bailey, Leighann
    Janney, Dorothea
    Lu, Cynthia
    Friedman, Henry S.
    NEURO-ONCOLOGY, 2011, 13 : 89 - 90
12345